Raise, you may very well be right. The evidence is right in front of us. Just ironic and ridiculously frustrating that pre Priority Review Announcement, we are exactly where we expected to be (one month better from a timing perspective) but because of the chronology of events, the stock is significantly lower.
The cash raise gives us immense flexibility to fight multiple fronts (Eg sell this live saving drug, sue the FDA if need be, etc) so if there is a real conspiracy, AMRN has the resources to take them to task.
News 
Market Data 
Discover 
